Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Antigen-presenting cells

Matthew E Call, PhD
Section Editor
E Richard Stiehm, MD
Deputy Editor
Anna M Feldweg, MD


The mechanism by which an antigen triggers an adaptive immune response involves several steps. Potentially antigenic particles must be captured, processed, and presented in recognizable form to T cells with the appropriate concomitant signals. The cells that perform these functions are antigen-presenting cells (APCs). Most nucleated cells express at least some of the major histocompatibility complex (MHC) proteins required to present antigens to T cells, a feature that endows all cells with the potential to become targets of the immune response when damaged or infected. However, only a select subset of hematopoietic lineage cells possesses the specialized machinery required to efficiently activate or "prime" naïve T cells and thereby initiate a new adaptive immune response. These cells are "professional" APCs.

The antigen processing and T cell priming functions of APCs as well as clinical implications and applications of these cells are presented in this topic review. The cellular interactions that form the basis of the cellular immune response and an overview of MHC structure and function are presented separately. (See "The adaptive cellular immune response" and "Major histocompatibility complex (MHC) structure and function".)

Professional APCs — There are three professional APCs:


Dendritic cells


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Oct 8, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Pamer E, Cresswell P. Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol 1998; 16:323.
  2. Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A 1997; 94:10850.
  3. Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329:506.
  4. Villadangos JA, Ploegh HL. Proteolysis in MHC class II antigen presentation: who's in charge? Immunity 2000; 12:233.
  5. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003; 3:472.
  6. Cresswell P. Invariant chain structure and MHC class II function. Cell 1996; 84:505.
  7. Riberdy JM, Newcomb JR, Surman MJ, et al. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992; 360:474.
  8. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996; 274:618.
  9. Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368:215.
  10. Inaba K, Turley S, Iyoda T, et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000; 191:927.
  11. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255.
  12. Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002; 9:2.
  13. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808.
  14. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3:867.
  15. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17:131.
  16. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4:349.
  17. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398:77.
  18. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5:678.
  19. Heath WR, Belz GT, Behrens GM, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199:9.
  20. Plemper RK, Wolf DH. Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem Sci 1999; 24:266.
  21. Houde M, Bertholet S, Gagnon E, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425:402.
  22. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 2006; 176:6770.
  23. Burgdorf S, Kautz A, Böhnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007; 316:612.
  24. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285:221.
  25. Porcelli SA, Segelke BW, Sugita M, et al. The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998; 19:362.
  26. Zeng Z, Castaño AR, Segelke BW, et al. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 1997; 277:339.
  27. Jayawardena-Wolf J, Bendelac A. CD1 and lipid antigens: intracellular pathways for antigen presentation. Curr Opin Immunol 2001; 13:109.
  28. Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002; 169:7111.
  29. Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298:347.
  30. Liljeqvist S, Ståhl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73:1.